The Global Vaccine Safety Initiative: Enhancing vaccine pharmacovigilance capacity at country level

Abstract

Large-scale immunization programmes now extend to all parts of the world, in- cluding least developed countries, where they reach unprecedented numbers of people. e number of vaccine doses administered worldwide continues to increase as new vaccines are developed and made available, and more people have access to immunization services. Development of immunization pro- grammes in low- and middle-income countries (LMICs) has increased im- munization coverage, which in turn has led to a reduction in vaccine-preventable diseases. However, as vaccine use has increased in LMICs, so has public atten- tion to vaccine safety issues, as happened previously in high-income countries. is has created additional vulnerabil- ity for all immunization programmes. Whether or not they are well founded, concerns about serious adverse events following immunization may rapidly undermine public condence and be- come a serious threat to eective vacci- nation strategies, eroding the enormous gains in disease control achieved with decades of eort.

(PDF) The Global Vaccine Safety Initiative: Enhancing vaccine pharmacovigilance capacity at country level. Available from: https://www.researchgate.net/publication/267929878_The_Global_Vaccine_Safety_Initiative_Enhancing_vaccine_pharmacovigilance_capacity_at_country_level [accessed Nov 23 2018].